Abstract
The haemodynamic effects of a new beta 1-adrenoceptor partial agonist, ICI 118,587, were studied in 10 patients with dilated cardiomyopathy and moderate to severe cardiac failure. Simultaneous right and left heart catheterisations were performed. Resting central haemodynamic indices were measured before and 15 min after an intravenous dose of 0.05 mg/kg and then 15 min after an additional intravenous dose of 0.15 mg/kg of ICI 118,587. Left ventricular performance was improved--as shown by significant increases in systolic left ventricular pressure, maximum rate of rise in left ventricular pressure (dP/dt max), and cardiac output and a decrease in left ventricular end diastolic pressure--without an undesirable increase in heart rate. The top of the dose response curve was reached after the lower dose. An important unwanted effect was seen in the most severely diseased patient, whose left ventricular systolic pressure, dP/dt max, and cardiac output decreased. This was probably due to the drug's antagonistic property supervening in this patient, who probably had high concentrations of circulating catecholamines. It is concluded that ICI 118,587 has a positive inotropic action and improves cardiac performance in patients with dilated cardiomyopathy and moderate cardiac failure, although care should be exercised when the drug is given intravenously in severe failure.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Awan N. A., Needham K. E., Evenson M. K., Win A., Mason D. T. Hemodynamic actions of prenalterol in severe congestive heart failure due to chronic coronary disease. Am Heart J. 1981 Feb;101(2):158–161. doi: 10.1016/0002-8703(81)90659-1. [DOI] [PubMed] [Google Scholar]
- Doherty J. E., Kane J. J. Clinical pharmacology of digitalis glycosides. Annu Rev Med. 1975;26:159–171. doi: 10.1146/annurev.me.26.020175.001111. [DOI] [PubMed] [Google Scholar]
- Kirlin P. C., Pitt B. Hemodynamic effects of intravenous prenalterol in severe heart failure. Am J Cardiol. 1981 Mar;47(3):670–675. doi: 10.1016/0002-9149(81)90553-1. [DOI] [PubMed] [Google Scholar]
- Levine T. B., Francis G. S., Goldsmith S. R., Simon A. B., Cohn J. N. Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure. Am J Cardiol. 1982 May;49(7):1659–1666. doi: 10.1016/0002-9149(82)90243-0. [DOI] [PubMed] [Google Scholar]
- Nuttall A., Snow H. M. The cardiovascular effects of ICI 118,587: A beta 1-adrenoceptor partial agonist. Br J Pharmacol. 1982 Oct;77(2):381–388. doi: 10.1111/j.1476-5381.1982.tb09309.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Pouleur H., Rousseau M. F., Mengeot P., Veriter C., Vincent M. F., Brasseur L. A. Improvement of global and regional left ventricular function in patients with previous myocardial infarction by a new beta 1 adrenoceptor partial agonist, ICI 118,587. Eur Heart J. 1982 Dec;3 (Suppl 500):123–127. [PubMed] [Google Scholar]
- Stoner J. D., 3rd, Bolen J. L., Harrison D. C. Comparison of dobutamine and dopamine in treatment of severe heart failure. Br Heart J. 1977 May;39(5):536–539. doi: 10.1136/hrt.39.5.536. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Swedberg K., Hjalmarson A., Waagstein F., Wallentin I. Prolongation of survival in congestive cardiomyopathy by beta-receptor blockade. Lancet. 1979 Jun 30;1(8131):1374–1376. doi: 10.1016/s0140-6736(79)92010-5. [DOI] [PubMed] [Google Scholar]